NO975738D0 - Modulering av kalsiumkanaler - Google Patents

Modulering av kalsiumkanaler

Info

Publication number
NO975738D0
NO975738D0 NO975738A NO975738A NO975738D0 NO 975738 D0 NO975738 D0 NO 975738D0 NO 975738 A NO975738 A NO 975738A NO 975738 A NO975738 A NO 975738A NO 975738 D0 NO975738 D0 NO 975738D0
Authority
NO
Norway
Prior art keywords
calcium channels
modulation
pharmaceutically
alkyl
phenyl
Prior art date
Application number
NO975738A
Other languages
English (en)
Other versions
NO975738L (no
Inventor
Nancy L Bowling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975738D0 publication Critical patent/NO975738D0/no
Publication of NO975738L publication Critical patent/NO975738L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/56Preparation of melamine
    • C07D251/58Preparation of melamine from cyanamide, dicyanamide or calcium cyanamide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Soft Magnetic Materials (AREA)
NO975738A 1995-06-07 1997-12-05 Modulering av kalsiumkanaler NO975738L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/485,317 US5532254A (en) 1995-06-07 1995-06-07 Modulation of calcium channels using benzothiophenes
PCT/US1996/009161 WO1996039833A1 (en) 1995-06-07 1996-06-04 Modulation of calcium channels

Publications (2)

Publication Number Publication Date
NO975738D0 true NO975738D0 (no) 1997-12-05
NO975738L NO975738L (no) 1997-12-05

Family

ID=23927688

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975738A NO975738L (no) 1995-06-07 1997-12-05 Modulering av kalsiumkanaler

Country Status (19)

Country Link
US (1) US5532254A (no)
EP (1) EP0873051B1 (no)
JP (1) JPH11506787A (no)
KR (1) KR19990022365A (no)
CN (1) CN1094758C (no)
AT (1) ATE272315T1 (no)
AU (1) AU692400B2 (no)
CA (1) CA2222739A1 (no)
CZ (1) CZ288547B6 (no)
DE (1) DE69633070D1 (no)
EA (1) EA000873B1 (no)
HU (1) HUP9900860A3 (no)
IL (1) IL122282A (no)
NO (1) NO975738L (no)
NZ (1) NZ310177A (no)
PL (1) PL323930A1 (no)
RO (1) RO117892B1 (no)
UA (1) UA42837C2 (no)
WO (1) WO1996039833A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
CZ300341B6 (cs) 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ES2232946T3 (es) 1997-04-30 2005-06-01 Eli Lilly And Company Agentes antitromboticos.
JP2002514217A (ja) 1997-04-30 2002-05-14 イーライ・リリー・アンド・カンパニー 抗血栓物質
JP2001522373A (ja) 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー 抗血栓剤
JP2002513415A (ja) * 1997-04-30 2002-05-08 イーライ・リリー・アンド・カンパニー 抗血栓剤
US5760030A (en) * 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
EP0997460B1 (en) * 1998-10-28 2002-12-11 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
EP1533295A1 (en) * 2003-11-24 2005-05-25 Newron Pharmaceuticals S.p.A. Cyclopentyl Derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
UA32427C2 (uk) * 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Also Published As

Publication number Publication date
IL122282A0 (en) 1998-04-05
EP0873051A1 (en) 1998-10-28
DE69633070D1 (de) 2004-09-09
RO117892B1 (ro) 2002-09-30
CZ388097A3 (cs) 1998-06-17
ATE272315T1 (de) 2004-08-15
CZ288547B6 (cs) 2001-07-11
IL122282A (en) 2001-08-08
WO1996039833A1 (en) 1996-12-19
HUP9900860A2 (hu) 1999-09-28
EA199800019A1 (ru) 1998-06-25
EP0873051B1 (en) 2004-08-04
EA000873B1 (ru) 2000-06-26
AU6091896A (en) 1996-12-30
UA42837C2 (uk) 2001-11-15
HUP9900860A3 (en) 1999-11-29
PL323930A1 (en) 1998-04-27
AU692400B2 (en) 1998-06-04
CA2222739A1 (en) 1996-12-19
CN1192121A (zh) 1998-09-02
NO975738L (no) 1997-12-05
US5532254A (en) 1996-07-02
EP0873051A4 (en) 1999-01-07
CN1094758C (zh) 2002-11-27
NZ310177A (en) 2000-06-23
JPH11506787A (ja) 1999-06-15
KR19990022365A (ko) 1999-03-25

Similar Documents

Publication Publication Date Title
NO975738D0 (no) Modulering av kalsiumkanaler
DE69505651D1 (de) Hemmen von haarwuchs
TR199700419A2 (xx) Yeni piridazinon t�revleri.
DE69628556D1 (de) Tricyclische verbindungen als inhibitoren von farnesyl protein transferase
ES2127397T3 (es) Sulfonamidas y sus derivados que modulan la actividad de la endotelina.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
DE69412049D1 (de) Hemmung von dysfunctionalen Uterusblutungen
SE9302431D0 (sv) Use of indenoindole compounds
DE69726716D1 (de) Antikachektische zusammensetzung
TW342389B (en) Arylalkyl-thiadiazinones
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
DK0458950T3 (da) Stabilisering af K2P pro
EA199800015A1 (ru) Способ ингибирования меланомы
MX9709542A (es) Modulacion de los canales de calcio.
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering
PL324086A1 (en) Antagonists of calcium passages
TW325463B (en) 4-Aminobenzoylguanidine-derivatives
EA199800366A1 (ru) Способы ингибирования ингибитора 1 активатора плазминогена
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
GB2158724A (en) Material of connective elements for soft tissues and internal organs
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
DE69509657D1 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application